RECSilicon

News

Reuters - 23 hours ago

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Monte dei Paschi di Siena, Apollo Global Management, updates Coeur Mining Oct 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1950 GMT on Friday: ** Italy aims to sell up to around 15% of Monte dei Paschi di Siena BMPS.MI in an upcoming share placement, reducing the government's stake in the bailed-out bank to as low as 12%, two sources close to the matter told Reuters on Friday.

Reuters - 1 day ago

Recordati looks for M&A deal in rare diseases, specialty, primary care sectors

BRIEF-Recordati looks for M&A deal in rare diseases, specialty, primary care sectors Oct 4 (Reuters) - Recordati CEO Rob Koremans tells analysts: CONTINUES TO LOOK FOR A M&A DEAL, LOOKS AT RARE DISEASES, SPECIALTY AND PRIMARY CARE SECTORS Further company coverage: RECI.MI

Reuters - 1 day ago

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Friday: ** Italian pharma group Recordati RECI.MI said it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease, a rare autoimmune disorder, for $825 million, sending both stocks up in early trade.

Reuters - 1 day ago

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

UPDATE 1-Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln Adds share moves, trader comment in paragraphs 3-4 Oct 4 (Reuters) - Italian pharma group Recordati RECI.MI said on Friday it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million, sending both stocks up in early trade.

Reuters - 1 day ago

Recordati rises after $825 mln global drug rights deal with Sanofi

BUZZ-Recordati rises after $825 mln global drug rights deal with Sanofi ** Shares of Recordati RECI.MI rise around 5% after the Italian pharma group said it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million ** "Very positive deal which optimises produc

Reuters - 1 day ago

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln Oct 4 (Reuters) - Italian pharma group Recordati RECI.MI said on Friday it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million. The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject to regulatory approval, the Italian company said.

Reuters - 1 day ago

Recordati Signs $825 Mln Deal With Sanofi To Buy Global Rights To Enjaymo

BRIEF-Recordati Signs $825 Mln Deal With Sanofi To Buy Global Rights To Enjaymo Oct 4 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : SIGNS DEAL WITH SANOFI TO BUY GLOBAL RIGHTS OF ENJAYMO TO PAY UP-FRONT $825 MILLION, ADDITIONAL PAYMENTS CONNECTED TO COMMERCIAL RESULTS UP TO $250 MILLION CLOSING EXPECTED BY YEAR-END, SUBJECT T

Reuters - 1 day ago

Italy - Factors to watch on October 4

Italy - Factors to watch on October 4 The following factors could affect Italian markets on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . ECONOMY ISTAT releases Q2 deficit/GDP ratio data (0800 GMT) and August retail sales data (1000 GMT).

Reuters - 2 months ago

Admiral, UCB SA, Victrex

EUROPE RESEARCH ROUNDUP-Admiral, UCB SA, Victrex Aug 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Admiral, UCB SA and Victrex, on Wednesday. HIGHLIGHTS * Admiral ADML.L : RBC raises target price to 3,550p from 3,400p * Demant A/S DEMANT.CO : Morgan Stanley raises to overweight from underweight * UCB SA UCB.BR : JP Morgan raises to overweight from neutral * Victrex Plc VCTX.L : Jefferies raises to hold from underperform * Watki

Reuters - 2 months ago

Italy's Recordati hikes 2024 guidance after core profit rises 11.5%

Italy's Recordati hikes 2024 guidance after core profit rises 11.5% July 30 (Reuters) - Italian drug maker Recordati RECI.MI raised its guidance for 2024 on Tuesday buoyed by positive momentum in its mainline Specialty and Primary Care and Rare Disease segments and an 11.5% rise in first-half core profit. The Milan-based company raised its earnings before interest, taxes, depreciation and amortization (EBITDA) forecast to between 845 million and 865 million euros ($915-$937 million) from a range

Reuters - 2 months ago

Recordati H1 EBITDA EUR 452.9 Mln

BRIEF-Recordati H1 EBITDA EUR 452.9 Mln July 30 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : SEES 2024 EBITDA IN RANGE OF EUR 845-865 MILLION, EBITDA MARGIN AROUND 24.5% H1 REVENUE EUR 1.2 BILLION H1 ADJUSTED NET PROFIT EUR 301.0 MILLION H1 EBITDA EUR 452.9 MILLION SEES 2024 ADJUSTED NET PROFIT BETWEEN EUR 560 AND 580 MILLIO

Reuters - 2 months ago

Italy - Factors to watch on July 30

Italy - Factors to watch on July 30 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS Chinese President Xi Jinping and Italian Prime Minister Giorgia Meloni discussed the war in Ukraine and the crisis in the Middle East at a meeting in Beijing on Monday, Meloni's office said.

Reuters - 3 months ago

Italy - Factors to watch on July 9

Italy - Factors to watch on July 9 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . DEBT Treasury to sell up to 8.5 billion euros in bonds at July 11 auction .

Reuters - 3 months ago

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Liberty Global, Crest Nicholson, NCR Voyix and Baxter International July 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2 000 GMT on Friday: * * Private equity firm Carlyle Group is in exclusive talks to acquire Baxter International's BAX.N kidney care spinoff Vantive for more than $4 billion, including debt, a person familiar with the matter told Reuters.

Reuters - 3 months ago

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Thyssenkrupp, Dompe Farmaceutici, Crest Nicholson Updates: BBVA July 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Friday: ** Thyssenkrupp TKGA.DE , Salzgitter SZGG.DE and France's Vallourec VLLP.PA are reviewing a sale of their steel joint venture HKM after they were approached by a potential buyer, Germany's largest steelmaker said.

Reuters - 3 months ago

Italy's Dompe not interested in possible deal with rival drugmaker Recordati

Italy's Dompe not interested in possible deal with rival drugmaker Recordati MILAN, July 5 (Reuters) - Italy's Dompe Farmaceutici is not interested in rival drugmaker Recordati RECI.MI , the biopharmaceutical group's chief executive and chairman said on Friday. "We had looked at it... it is a large company ...we are not on the file," Sergio Dompe told Reuter.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

RECSilicon

News

Conditions

Popular Assets

XM Live Chat